Twelfth Arden House European Conference March 12-14, 2007

Twelfth Arden House European Conference March 12-14, 2007
London, UK
The parenteral route remains an important route of delivery of medicines forthe pharmaceutical industry for both small molecules and, increasingly,biologics. This conference will address the current best practices,challenges and trends associated with the development, manufacture andregistration of parenteral products.
This Conference will focus on the following topics:? Top issues for parenteral dosage form development? Risk-based approach to development and manufacture? Development and manufacture of biologicals? Facilities, validation and plant design? Packaging and devices? Emerging new technologies ? Regulatory trends
The Conference will provide an intensive course of study for pharmaceuticalscientists working in all aspects of the research and development,production, registration and the licensing of parenteral dosage forms. Who should attend? Managers and scientists with responsibilities for allaspects from R & D, product development, manufacture, QA/QC, regulatoryaffairs and from the regulatory agencies.
Conference Chair
The Conference is led by Paul Gellert who is a Senior Principal Scientist atAstraZeneca covering the area of drug delivery globally, including parenteraldosage forms for both small molecules and biologics. He is a member ofthe Editorial Advisory Panel for Scrip?s Target world drug delivery newspublication, the Scientific Advisory Board of the Controlled Release Society,the UK Drug Delivery Network Steering Committee and a member of theEditorial Advisory Board for the journal Nanomedicine.
(44) (0) 20 75722261
Comments: 0